CONCORD BIOTECH
|
|
BOM : 543960     NSE : CONCORDBIO     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : NA |
Jul 26,2024 |
Price(EOD): ₹ 1,704.15
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 17,825.41 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
CONCORD BIOTECH | 2.5% | 14.2% | NA |
SUN PHARMACEUTICAL INDUSTRIES | 7.9% | 12.6% | 51.7% |
CIPLA | 5.9% | 6.7% | 43% |
DR REDDYS LABORATORIES | 1.8% | 13.6% | 29.6% |
ZYDUS LIFESCIENCES | 4.5% | 13.1% | 96.6% |
DIVIS LABORATORIES | 5.7% | 5.5% | 23.4% |
MANKIND PHARMA | -2.5% | -3.8% | 12.9% |
TORRENT PHARMACEUTICALS | 5.4% | 14.3% | 59.2% |
LUPIN | 1.9% | 16.1% | 92.7% |
FUNDAMENTAL ANALYSIS OF CONCORD BIOTECH
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF CONCORD BIOTECH
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
58.5
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 304.73 Cr
[Latest Qtr - Mar2024 - Consolidated Results ] 11.68
P/B Calculated based on Book Value of Rs 1,526.65 Cr
[Latest Year - Mar2024 - Consolidated Results ] 17.53
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,016.94 Cr
[Latest Qtr - Mar2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
31694% 21720% - |
SHARE PRICE MOMENTUM OF CONCORD BIOTECH
CONCORD BIOTECH vs SENSEX
DEBT OF CONCORD BIOTECH
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0.02 0.05 0.02 |
0 0.02 0.05 0.02 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF CONCORD BIOTECH
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF CONCORD BIOTECH
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
32.46% 26.77% 30.81% 30.4% |
17.02% 4.05% 4.22% 3.97% |
QtrlyTrend |
8 | |
Latest Qtr: Mar2024 | ||
Quarterly Result Analysis → |
CONCORD BIOTECH related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | 5.3% | 9.4% | 50.2% |
S&P BSE SMALL CAP | 3.5% | 4.3% | 59.2% |
S&P BSE MIDSMALLCAP | 3.3% | 4% | 60.1% |
S&P BSE 400 MIDSMALLCAP | 3.1% | 3.9% | 57.2% |
S&P BSE 250 SMALLCAP | 3% | 3.3% | 54.4% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MID SMALL400 | 3% | 3.4% | 56.7% |
NIFTY SMALLCAP250 | 2.8% | 3.4% | 59.3% |
NIFTY500 MULTICAP 50:25:25 | 2.2% | 3.9% | 43.6% |
NIFTY 500 | 1.9% | 4.1% | 36.7% |
You may also like the below Video Courses
FAQ about CONCORD BIOTECH
Is CONCORD BIOTECH good for long term investment?
As on Jul 26,2024, the Fundamentals of CONCORD BIOTECH look Strong and hence it may be good for long term investment! See Financial Performance of CONCORD BIOTECH . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is CONCORD BIOTECH UnderValued or OverValued?
As on Jul 26,2024, CONCORD BIOTECH is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of CONCORD BIOTECH ?
As on Jul 26,2024, the Intrinsic Value of CONCORD BIOTECH is Rs. 6.59 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 5.36
Fair Value [Median EV / Sales Model] : Rs. 7.81
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of CONCORD BIOTECH : Rs. 6.59
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.